Skip to main content
AmigoFish

Ep. 296 Overactive Bladder Management: Updates and Guidelines with Dr. Jason Kim

From BackTable Urology · · 44 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

What if we’re waiting too long to offer our OAB patients the treatments that actually work? In this episode of BackTable Urology, Dr. Jason Kim joins host Dr. Anjali Kapur to discuss updates in overactive bladder management and evolving guidelines, including a shift away from rigid stepwise care toward shared decision-making.

---

Get the BackTable app https://www.backtable.com/app

---

Timestamps

00:00 - Introduction 03:06 - 2024 AUA/SUFU Idiopathic OAB Guideline 07:32 - Patient Experience with OAB 11:59 - Beta-3 Agonists vs Anticholinergics 15:15 - Botox Counseling and Dosing 18:11 - Tibial Nerve Stimulation 25:47 - Sacral Neuromodulation 32:09 - Cost Burden of OAB 39:38 - Evolution of OAB Care 41:39 - Future Research Directions

---

More about this episode

The conversation positions OAB as a clinical diagnosis, supported by focused initial evaluation and selective use of advanced testing, with attention to the emerging role of ambulatory urodynamics. Dr. Kim and Dr. Kapur review management across the care continuum, including behavioral strategies, pelvic floor physical therapy, and pharmacologic options, with consideration of beta-3 agonists in older patients. The discussion also focuses on earlier use of minimally invasive therapies such as intradetrusor Botox and neuromodulation, and how introducing these options sooner may improve follow-up, reduce delays, and help patients achieve symptom control more efficiently.

---

Resources

The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder (2024) https://www.auanet.org/guidelines-and-quality/guidelines/idiopathic-overactive-bladder

Anticholinergic Drug Exposure and the Risk of Dementia https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2736353

Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial

https://pubmed.ncbi.nlm.nih.gov/20171677/

Trends in Utilization of Sacral Neuromodulation for Overactive Bladder: Insight From the AUA AQUA Registry https://www.auajournals.org/doi/10.1097/UPJ.0000000000000916

A retrospective longitudinal evaluation of new overactive bladder patients in an FPMRS urologist practice: Are patients following up and utilizing third-line therapies? https://pubmed.ncbi.nlm.nih.gov/33197059/

Back to BackTable Urology · Report a problem